Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Regulatory T cells are paramount effectors in progesterone regulation of embryo implantation and fetal growth
Ella S. Green, Lachlan M. Moldenhauer, Holly M. Groome, David J. Sharkey, Peck Y. Chin, Alison S. Care, Rebecca L. Robker, Shaun R. McColl, Sarah A. Robertson
Ella S. Green, Lachlan M. Moldenhauer, Holly M. Groome, David J. Sharkey, Peck Y. Chin, Alison S. Care, Rebecca L. Robker, Shaun R. McColl, Sarah A. Robertson
View: Text | PDF
Research Article Reproductive biology

Regulatory T cells are paramount effectors in progesterone regulation of embryo implantation and fetal growth

  • Text
  • PDF
Abstract

Progesterone (P4) is essential for embryo implantation, but the extent to which the pro-gestational effects of P4 depend on the maternal immune compartment is unknown. Here, we investigate whether regulatory T cells (Treg cells) act to mediate luteal phase P4 effects on uterine receptivity in mice. P4 antagonist RU486 administered to mice on days 1.5 and 3.5 postcoitum to model luteal phase P4 deficiency caused fewer CD4+Foxp3+ Treg cells and impaired Treg functional competence, along with dysfunctional uterine vascular remodeling and perturbed placental development in midgestation. These effects were linked with fetal loss and fetal growth restriction, accompanied by a Th1/CD8-skewed T cell profile. Adoptive transfer at implantation of Treg cells — but not conventional T cells — alleviated fetal loss and fetal growth restriction by mitigating adverse effects of reduced P4 signaling on uterine blood vessel remodeling and placental structure and by restoring maternal T cell imbalance. These findings demonstrate an essential role for Treg cells in mediating P4 effects at implantation and indicate that Treg cells are a sensitive and critical effector mechanism through which P4 drives uterine receptivity to support robust placental development and fetal growth.

Authors

Ella S. Green, Lachlan M. Moldenhauer, Holly M. Groome, David J. Sharkey, Peck Y. Chin, Alison S. Care, Rebecca L. Robker, Shaun R. McColl, Sarah A. Robertson

×

Figure 2

Impaired luteal phase P4 signaling causes CD4+ Treg cell deficiency in udLNs in midgestation.

Options: View larger image (or click on image) Download as PowerPoint
Impaired luteal phase P4 signaling causes CD4+ Treg cell deficiency in u...
Female C57BL/6 (B6) mice were mated to BALB/c males and administered RU486 (1 mg/kg) or vehicle (control) on 1.5 and 3.5 dpc, and then udLNs were excised from pregnant (≥1 viable implantation site) mice on 9.5 dpc. (A) Total cell count and number and proportion of CD4+ T cells in the udLNs of control and RU486-treated mice. (B) Representative FACS plots of Foxp3 staining in CD4+ T cells and Nrp1 staining in CD4+Foxp3+ T cells in the udLNs of control and RU486-treated mice. Among CD4+ T cells, Treg cells were defined as Foxp3+, thymic derived Treg (tTreg) cells were classified as Foxp3+Nrp1+, and peripherally induced Treg cells were classified as Foxp3+Nrp1–/lo. (C) Quantification of Foxp3+ Treg cell number; proportions of Foxp3+, Foxp3+Nrp1+, and Foxp3+Nrp1–/lo Treg cells (%CD4+ cells); and proportion of Foxp3+Nrp1+ cells (%Foxp3+ cells). (D) Representative FACS plots of IFNG and IL-17A staining in udLN CD4+Foxp3– T cells from control and treated mice. (E and F) Number and proportion (of CD4+ cells) of IFNG+ (Th1) cells (E) and IL-17+ (Th17) cells (F). Also shown is the geometric MFI of IFNG in Th1 cells (E) and IL-17 in Th17 cells (F). (G) Ex vivo analysis of suppressive activity in Treg (CD4+CD25+) cells isolated and pooled from udLNs of 1–3 pregnant control or RU486-treated mice on 8.5–9.5 dpc and coincubated with responder spleen conventional T (Tconv; CD4+CD25–) cells. Tconv cell proliferation was determined by CFSE staining and flow cytometry analysis. Proliferation of Tconv cells (%control, no Treg cells) at each Treg/Tconv ratio is depicted. (A, C, E, and F) n = 6–15 pregnant dams/group; data shown as mean ± SEM with individual mice indicated by symbols. (G) n = 9–10 cell pools/group in 7 experimental replicates; data shown as mean ± SEM with mean of biological replicates indicated by symbols. (A, C, E, F, and G) Data were analyzed by unpaired t test; *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts